Giant Biogene Holding Co., Ltd (02367) reported unchanged authorized share capital at 5,000,000,000 ordinary shares, each with a par value of USD 0.00001, totaling USD 50,000. As of the end of January 2026, the issued share count remained at 1,070,904,000 shares with no adjustments to treasury shares. Public float requirements continued to meet the 25% threshold established under applicable listing rules.

Under the 2023 Share Option Scheme, 256,000 options lapsed, leaving 11,600,000 outstanding at month-end. No new shares were issued from these options, and no treasury shares were transferred during the period. A prior repurchase of 9,200,000 shares on 13 June 2025 remained not yet canceled, though there was no net change in issued or treasury shares for January 2026.